Globally considered, these studies all suggest that patients with t(4;11)(q21;q23)/MLL-AF4 positive ALL have a poor clinical outcome compared to others non-high-risk patients and are potential candidates for postinduction intensification with HSCT in presence of an HLA-matched family donor. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.